SEED Therapeutics Receives IND Clearance from China’s NMPA for ST-01156
China Sites to Join Upcoming Global Expansion Study Evaluating RBM39-Dependent Cancers King of Prussia, PA – November 12, 2025 – SEED Therapeutics, Inc. (“SEED”),…
Blog
SEED Therapeutics Completes $30 Million Series A-3 Financing
King of Prussia, PA – September 23, 2025 – SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable…
20 Years of the Ubiquitin Revolution: Honoring Nobel Laureate Professor Avram Hershko and the Future of Targeted Protein Degradation
New York, NY – September 9, 2025 – Leaders in the fields of ubiquitin biology and targeted protein degradation (TPD) gathered on September 6, 2025,…
SEED Therapeutics Named Finalist for 2025 Prix Galien USA “Best Start-Up” Award
Nomination recognizes SEED’s pioneering work in molecular glue development in targeted protein degradation to address high unmet medical needs Follows recent FDA IND clearance…
FDA Clears IND for SEED Therapeutics’ RBM39 Degrader ST-01156
First Patient Dosing Expected in Q1 2026 Clinical Trial to Prioritize Biomarker-Selected RBM39-Dependent Cancers King of Prussia, PA – August 11, 2025 –…
SEED Therapeutics Appoints Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer
King of Prussia, PA – June 9, 2025 – SEED Therapeutics Inc. (“SEED”), a biotechnology company pioneering targeted protein degradation (TPD) through the discovery of…
SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025
Novel RBM39 molecular glue achieves complete tumor regression in mechanism-based Ewing sarcoma models; IND filing expected mid-2025 Dual PROTAC strategy overcomes hook effect and…
SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago
Two PROTAC synergy using two E3 ligases for achieving levels of degradation of KRAS G12D not achieved with single PROTACs, will be presented by…
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
King of Prussia, PA – January 28, 2025 – SEED Therapeutics Inc. (“SEED”), a biotechnology company pioneering the discovery of molecular glues for targeted protein…
Nature: Protein degraders push into novel target space
Clinic-ready molecular glues and heterobifunctional PROTAC drugs are taking targeted protein degradation into uncharted territory. Learn More